| Effects of lead exposure on proliferation and differentiation of neural stem cells derived from different regions of embryonic rat brain F Huang, JS Schneider Neurotoxicology 25 (6), 1001-1012, 2004 | 90 | 2004 |
| Effects of low-level lead exposure on cell survival and neurite length in primary mesencephalic cultures JS Schneider, FN Huang, MC Vemuri Neurotoxicology and teratology 25 (5), 555-559, 2003 | 41 | 2003 |
| 227Th-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study O Lindén, AT Bates, D Cunningham, C Hindorf, E Larsson, A Cleton, ... Cancer Biotherapy & Radiopharmaceuticals 36 (8), 672-681, 2021 | 20 | 2021 |
| Modulation of ATP levels alters the mode of hydrogen peroxide-induced cell death in primary cortical cultures: effects of putative neuroprotective agents F Huang, MC Vemuri, JS Schneider Brain research 997 (1), 79-88, 2004 | 20 | 2004 |
| Exposure–Response Modeling and Simulation of Progression‐Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer J Grevel, G Jentsch, R Austin, NH Prins, J Lettieri, D Mitchell, F Huang, ... Clinical and Translational Science 12 (5), 459-469, 2019 | 8 | 2019 |
| A phase I study to determine the effect of regorafenib (REG) on the pharmacokinetics (PK) of substrates of P-glycoprotein (P-gp; digoxin) and breast cancer resistant protein … D Strumberg, SE Al-Batran, I Takacs, L Géczi, A Cleton, F Huang, ... Annals of Oncology 27, vi156, 2016 | 7 | 2016 |
| A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma W Liu, L Ping, Y Xie, Y Sun, T Du, Y Niu, G Cisternas, F Huang, ... Cancer Chemotherapy and Pharmacology 89 (6), 825-831, 2022 | 6 | 2022 |
| Clinical pharmacokinetics of the androgen receptor inhibitor darolutamide in healthy subjects and patients with hepatic or renal impairment C Zurth, P Nykänen, G Wilkinson, P Taavitsainen, A Vuorela, F Huang, ... Clinical Pharmacokinetics, 1-11, 2022 | 6 | 2022 |
| A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors C Weekes, AC Lockhart, JJ Lee, I Sturm, A Cleton, F Huang, HJ Lenz International journal of cancer 145 (9), 2450-2458, 2019 | 5 | 2019 |
| Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors F Marmé, C Gomez-Roca, K Graudenz, F Huang, J Lettieri, C Peña, ... Cancer Chemotherapy and Pharmacology 81, 727-737, 2018 | 3 | 2018 |
| Abstract CT148: A phase Ib study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors C Weekes, AC Lockhart, HJ Lenz, JJ Lee, A Cleton, F Huang, I Sturm Cancer Research 76 (14_Supplement), CT148-CT148, 2016 | 3 | 2016 |
| Alzheimer's disease in male veterans: Prevalence and risk factors X Hengge, W Luning, W Zhenfu, W Xiaohong, H Funan Neurobiology of Aging, 33, 2000 | 3 | 2000 |
| Experiment on safety considerations in normal and infarct rats transcranially stimulated with magnetic fields FN Huang, QL Cao, DG Sheng Chin J Phys Med (Chinese) 20 (8), 136-139, 1998 | 3 | 1998 |
| 260P A phase I study of copanlisib, a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, in Chinese patients with relapsed indolent non-Hodgkin lymphoma (iNHL) Y Song, W Liu, Y Niu, G Cisternas, F Huang, J Garcia-Vargas, BH Childs, ... Annals of Oncology 31, S1344, 2020 | 2 | 2020 |
| Prolonged response to regorafenib in a patient with iodine refractory thyroid cancer SK Wong, QSC Chu, JL Spratlin, R Sangha, AJB McEwan, DW Morrish, ... Case Reports in Oncology 12 (3), 791-795, 2020 | 2 | 2020 |
| PHYSIOLOGICALLY-BASED PHARMACOKINETIC AND CLINICAL STUDY TO ASSESS EFFECTS OF CYP3A INDUCTION AND INHIBITION ON COPANLISIB PK IN CANCER PATIENTS. JF Schlender, J Grevel, S Frechen, C Diedrich, R Burghaus, A Spreafico, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 105, S70-S70, 2019 | 2 | 2019 |
| No effect of levothyroxine and levothyroxine-induced subclinical thyrotoxicosis on the pharmacokinetics of sorafenib in healthy male subjects F Huang, A Ajavon, E Huang, J Lettieri, R Liu, C Peña, M Berse Thyroid 27 (9), 1118-1127, 2017 | 2 | 2017 |
| Phase I dose-escalation study of the pan-PI3 K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors M Macy, T Cash, N Pinto, JG Pressey, L Szalontay, WL Furman, ... European Journal of Cancer 174, S28-S29, 2022 | 1 | 2022 |
| Abstract P239: Safety and efficacy of copanlisib in combination with nivolumab: A phase Ib study in patients with advanced solid tumors BA Carneiro, R Jotte, N Gabrail, O Hamid, F Huang, S Chaturvedi, ... Molecular Cancer Therapeutics 20 (12_Supplement), P239-P239, 2021 | 1 | 2021 |
| EFFECT OF HEPATIC AND RENAL IMPAIRMENT ON THE PHARMACOKINETICS OF COPANLISIB. C Granvil, N Chattopadhyay, A Kohnke, G Cisternas, M Gurniak, M Wang, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 109, S13-S13, 2021 | 1 | 2021 |
